You are here: Industry Insights > InnoCare

News List

Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022 ASCO Annual Meeting PharmaSources.com
June 07, 2022
Latest data of InnoCare’s robust oncology pipeline were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
InnoCare Announces Dosing of First Patient in Clinical Trial of RTK Inhibitor ICP-033 in China PharmaSources.com
March 30, 2022
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases...
InnoCare Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China PharmaSources.com
March 28, 2022
InnoCare Pharmaannounced today that the company has received Investigational New Drug (IND) approval of clinical trial from the NMPA...
InnoCare Releases 2021 Annual Results and Business Highlights InnoCare
March 23, 2022
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing...
InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Waldenström’s Macroglobulinemia in China March 14, 2022
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced recently...
InnoCare to Host 2021 Full Year Earnings Call on March 23, 2022 InnoCare Pharma
March 11, 2022
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases...
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development PharmaSources.com
January 07, 2022
InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company executives will attend the upcoming investor conferences organized by Morgan Stanley and UBS to share company’s latest development.
Orelabrutinib Data Presented at the 63rd Annual Meeting of ASH prnasia
December 14, 2021
InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that leading PIs presented latest data of BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH) Annual Meeting...
InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List prnasia
December 03, 2021
InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement Drug List (NRDL)...
InnoCare Announces the Clearance of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 by U.S. FDA prnasia
November 15, 2021
InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today the Investigational New Drug (IND) clearance of its SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase)...

Previous page 1 2 3 4 5 6 7 Next page